BioLineRx Presents Data Demonstrating the Potential for BL-1020 to Improve Cognitive Deficits in Preclinical Models
News May 19, 2009
BioLineRx Ltd. has announced that data from preclinical behavioral models of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia, were presented at the Society of Biological Psychiatry (SOBP) 64rd Annual Scientific Convention & Meeting held in Vancouver, Canada May 14-16, 2009.
Recent data demonstrate that BL-1020 can repair chronic cognitive deficits in animal models, potentially via enhanced dopamine release in the pre-frontal cortex. Dr. Jo Neill, Professor of Psychopharmacology, at the School of Pharmacy, University of Bradford in UK, has presented the findings.
”We are pleased to present these data at this important psychiatric conference. The potential of improving cognition addresses the unmet medical need in schizophrenia and supports our target product profile of developing a highly efficacious antipsychotic without compliance limiting extrapyramidal or metabolic side effects with the potential to improve cognition,” commented Morris C. Laster, MD, chief executive officer of BioLineRx.
“We believe that the compound holds great promise for the treatment of schizophrenia, and are pleased to report that the ISMB has reviewed the safety data of the first 200 patients who completed the 6 week trial and did not report any safety concerns related to the trial. We are eagerly awaiting the results of our phase IIb EAGLE trial expected in Q3 of 2009”
Autism Risk Higher if Pregnant Mothers Have Infection Requiring HospitalizationNews
Studies have shown that mothers who experience an infection severe enough to require hospitalization during pregnancy are at higher risk of having a child with autism.READ MORE
£2.2M Collaboration to Fuel Drug Developments for HIVNews
A collaboration between the University of Liverpool and the Johns Hopkins University School of Medicine (JHUSM) has been awarded a further £2.2M ($3M) to develop sophisticated new medicines for HIV.READ MORE
Antibody Treatment Effective in Treatment-Resistant COPD PatientsNews
The new study reports the results from two Phase III clinical trials evaluating the efficacy of mepolizumab, an antibody treatment that reduces the number of eosinophils in the blood, in moderate to severe treatment-resistant eosinophilic COPD.READ MORE
Comments | 0 ADD COMMENT
22nd Edition of International Conference on Biotechnology
Apr 16 - Apr 18, 2018